Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

CASPIAN investigators

研究成果: 雜誌貢獻文章同行評審

116 引文 斯高帕斯(Scopus)

指紋

深入研究「Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial」主題。共同形成了獨特的指紋。

Medicine & Life Sciences